Novo Nordisk to Establish New Production Facility in Denmark with $1.2 Billion Investment

16 December 2024: Novo Nordisk, a leading global healthcare company has unveiled plans to invest $1.2 bn in the construction of a brand-new production facility in Odense, Denmark. This project marks the company’s first establishment of a new production site in Denmark in over two decades, underscoring a significant milestone in Novo Nordisk’s commitment to expanding its production capabilities.

Spanning over 40,000 m², the state-of-the-art facility will include a finished production unit and a warehouse, designed with modular and flexible features to accommodate a wide range of products. These will include treatments for rare diseases such as haemophilia, addressing both current and future needs.

In an official press release by the company, Henrik Wulff, Executive Vice President of Product Supply, Quality & IT at Novo Nordisk stated, "The facility will leverage advanced technology and innovative equipment to ensure the highest quality for patients while meeting the growing global demand for our life-changing medicines." He further added, "We are excited to build on our legacy in Denmark and embark on this journey in Odense, a well-connected city with a vibrant community and skilled workforce."

The new facility reflects Novo Nordisk’s strong commitment to sustainability. The site will feature solar panels for on-site electricity generation, and the surrounding landscape will be enhanced with over 4,000 new trees, lakes, forests, and public community spaces. The project will reuse excess soil, wooden materials, and other sustainable resources to minimize its environmental footprint while preserving the natural beauty of the area.

Construction of the facility has already begun and is expected to be completed by 2027. Once operational, the site will create 400 permanent jobs, with an additional 1,000 external workers engaged during the construction phase.

This landmark investment underscores Novo Nordisk’s unwavering commitment to tackling global healthcare challenges while prioritizing sustainability, innovation, and local economic growth. It reinforces the company’s dedication to expanding access to high-quality treatments worldwide, fostering a sustainable future, and strengthening its presence in Denmark.